US FDA approves Regeneron Pharma’s Libtayo in combination with chemotherapy as first-line treatment for advanced NSCLC

Press/Media

Period	10 Nov 2022

Media coverage

Title	US FDA approves Regeneron Pharma’s Libtayo in combination with chemotherapy as first-line treatment for advanced NSCLC
Media name/outlet	PharmaBiz
Country/Territory	India
Date	10/11/22
URL	ct.moreover.com/?a=49216240027&p=1gw&v=1&x=4L9icuntVyFAfEOJlO50bQ
Persons	Israel Lowy,